LA46-8
Other
Active
Answer Lists using this Answer Code
Answer List | Answer List Name | Externally Defined |
---|---|---|
LL1002-6 | PhenX05_15_30D cereal amt | N |
LL1087-7 | PhenX06_10_res water supply | N |
LL1106-5 | PhenX06_28_workspace floor material | N |
LL1108-1 | PhenX06_30_home repairs | N |
LL1117-2 | PhenX07_08_gallstone dx method | N |
LL1125-5 | PhenX07_16_chemo drugs | N |
LL1126-3 | PhenX07_17_hormone therapy drugs | N |
LL1132-1 | PhenX07_23_stop pain med reason | N |
LL1141-2 | PhenX08_08_child beverage between meals | N |
LL1153-7 | PhenX08_20_dentist visit reason | N |
LL1154-5 | PhenX08_21_pain duration | N |
LL118-1 | CR_160_Race | N |
LL119-9 | CR_161_Race2 | N |
LL1191-7 | PhenX10_02_male infertility probs | N |
LL1195-8 | PhenX10_06_birth control methods | N |
LL1213-9 | PhenX10_24_natural hormones | N |
LL1232-9 | PhenX10_43_pregnancy outcome | N |
LL1245-1 | PhenX11_07_child strabismus tx | N |
LL1246-9 | PhenX11_08_myopia tx | N |
LL1248-5 | PhenX11_10_glaucoma drops | N |
LL127-2 | CR_170_Race coding system | N |
LL133-0 | CR_1790_Follow up source | N |
LL1337-6 | PhenX12_67_job schedule | N |
LL1338-4 | PhenX12_68_job shift | N |
LL1423-4 | PhenX14_17_aids for walk | N |
LL1431-7 | PhenX14_25_reason no actigraph | N |
LL1443-2 | PhenX03_15_lifetime drug use type | N |
LL1474-7 | PhenX07_39_ menopause cause | N |
LL1543-9 | Phenx11_42_relatives | N |
LL1549-6 | Phenx11_47_glaucoma treatment | N |
LL1566-0 | PhenX13_43_body part | N |
LL1628-8 | PhenX18_11_languages | N |
LL1632-0 | PhenX18_15_fracture confirmation source | N |
LL1633-8 | PhenX18_16_hip fracture location | N |
LL1634-6 | PhenX18_17_fracture treatment | N |
LL1635-3 | PhenX18_18_fracture circumstances | N |
LL1636-1 | PhenX18_19_trauma location | N |
LL1637-9 | PhenX18_20_time of fracture | N |
LL1639-5 | PhenX18_22_fracture location detail | N |
LL1654-4 | PhenX18_26_race, ethnicity | N |
LL1658-5 | PhenX19_04_Dr. reported pain cause | N |
LL1660-1 | PhenX19_06_reason Dr. visit | N |
LL1672-6 | PhenX19_18_diagnostic, staging procedure | N |
LL1677-5 | PhenX19_23_CA histopathology type | N |
LL1693-2 | PhenX19_39_bleeding site | N |
LL1735-1 | FeedingType | N |
LL1736-9 | MaternalFactors | N |
LL1752-6 | PhenX21_02_reason for experience | N |
LL1766-6 | PhenX16_07_main symptom | N |
LL1772-4 | PhenX16_13-medical hx | N |
LL1775-7 | PhenX16_16_infectious diseases | N |
LL1832-6 | NEMSIS_45_protocol used | N |
LL1862-3 | PhenX19_45_initial visit reason | N |
LL1865-6 | PhenX19_48_autoimmune diseases | N |
LL1874-8 | FMQAI_03_self dialysis training | N |
LL1884-7 | FMQAI_05_Reason no transplant info given | N |
LL1889-6 | FMQAI_10_Dialysis at time of death | N |
LL1890-4 | FMQAI_11_Reason therapy disconintued | N |
LL1891-2 | FMQAI_12_Payment source | N |
LL1898-7 | PhenX15_11 | N |
LL1910-0 | FMQAI_17_Place of death | N |
LL1914-2 | SAMSHA_01_sources of stress | N |
LL1916-7 | SAMSHA_03_occupational status | N |
LL1955-5 | PhenX16_25_Booster type | N |
LL1974-6 | NEMSIS_83_mech of injury | N |
LL2003-3 | OPTIMAL_Mobility aids | N |
LL2023-1 | NIH Stroke Scale Interval | N |
LL2104-9 | ESRD-Erythropoiesis-Stimulating Agent | N |
LL2105-6 | ESRD-medication route | N |
LL2116-3 | ESRD - information source | N |
LL2121-3 | NEMSIS-ECG type | N |
LL214-8 | CR_450_Site coding system | N |
LL2142-9 | ESRD-facilities-certified program | N |
LL216-3 | CR_470_Morphology coding system | N |
LL2164-3 | ESRD-graft assessment frequency | N |
LL2165-0 | ESRD-non-oral vitamin D analog | N |
LL2166-8 | ESRD-oral vitamin D analog | N |
LL2167-6 | ESRD-dialysis access exam frequency | N |
LL2172-6 | ESRD-IV iron type prescribed | N |
LL2173-4 | ESRD-oral iron type prescribed | N |
LL2190-8 | RHEA-perineal tear class | N |
LL2205-4 | CARE-LTCH - discharge location | N |
LL2239-3 | Adenovirus | N |
LL2266-6 | HCoV | N |
LL2267-4 | hMPV genotype | N |
LL2272-4 | RSV type | N |
LL2274-0 | Rhinovirus | N |
LL2344-1 | VAERS_Relation to patient | N |
LL236-1 | CR_930_Pathology stager | N |
LL2458-9 | Reason CCHD NBS not performed | N |
LL2513-1 | Type of place where birth occurred | N |
LL2517-2 | Cephalic-Breech-Other | N |
LL2532-1 | Death certificate_Transport Role of Decedent | N |
LL2563-6 | NTDS_F01_Payment source | N |
LL259-3 | OASIS_M0300_Current residence | N |
LL2685-7 | NTDS_DG_01_Co-morbid Conditions | N |
LL2759-0 | NTDS_Q_01_Hospital Complications | N |
LL2762-4 | NTDS_P_07_Transport mode | N |
LL2915-8 | CDC.CS_13_Mother's race | N |
LL2917-4 | CDC.CS_15_Mother's marital status | N |
LL2921-6 | CDC.CS_19_Mother's clinical stage of syphilis | N |
LL2922-4 | CDC.CS_20_Mother's surv stage of syphilis | N |
LL2925-7 | CDC.CS_22_Mother's treatment | N |
LL2930-7 | CDC.CS_32_Signs of CS | N |
LL2936-4 | CDC.CS_17_Treponemal test type | N |
LL3012-3 | PCORI_Information data source | N |
LL3017-2 | Discharge vital status | N |
LL3031-3 | Patient Residence Type | N |
LL3068-5 | MSCDM_Admitting Source | N |
LL3178-2 | US state or other_specify | N |
LL3179-0 | 20150106-APTASet1_2 | N |
LL3182-4 | 20150106-APTASet1_5 | N |
LL3185-7 | 20150106-APTASet1_8 | N |
LL3187-3 | 20150106-APTASet1_10 | N |
LL3195-6 | 20150106-APTASet1_18 | N |
LL3254-1 | Cardiac stress test types | N |
LL331-0 | OASIS_M0900_Nursing home admission | N |
LL3322-6 | Gender identity | N |
LL3323-4 | Sexual orientation | N |
LL350-0 | ART_1_Entry point | N |
LL3591-6 | Visual evoked potential results | N |
LL3592-4 | Electroretinography results | N |
LL3638-5 | Heparin| |
N |
LL3656-7 | [NHCS] Surgery 24H post-op follow-up outcomes | N |
LL3676-5 | [NHCS] Outpatient visit discharge disposition | N |
LL3677-3 | [NHCS] ED discharge disposition | N |
LL3699-7 | Coronary artery segments | N |
LL3702-9 | Cardiac procedure complications | N |
LL371-6 | HL79033_Program name | N |
LL3721-9 | Cardiac cath access sites | N |
LL3722-7 | [NEI] Amblyopia type | N |
LL3723-5 | [NEI] Coloboma location | N |
LL3724-3 | [NEI] Color vision findings | N |
LL3725-0 | [NEI] Color vision test method | N |
LL3727-6 | [NEI] Findings supporting myopathy | N |
LL3728-4 | [NEI] Type of congenital cranial dysinnervation (C | N |
LL3729-2 | [NEI] Gross eye defects | N |
LL373-2 | HL79034_Pt escort | N |
LL3730-0 | [NEI] Eye-related MRI findings | N |
LL3731-8 | [NEI] Inheritance pattern from family history | N |
LL3734-2 | [NEI] Oculary history | N |
LL3735-9 | [NEI] Corneal dystrophy type | N |
LL3738-3 | [NEI] Strabismus type | N |
LL3739-1 | [NEI] Ophthalmologic disease related systemic find | N |
LL3740-9 | [NEI] Tetraparesis type | N |
LL3741-7 | [NEI] Tissue types positive for axonal spheroids | N |
LL3743-3 | [NEI] Ocular alignment findings | N |
LL3744-1 | [NEI] Nystagmus null-point head posture | N |
LL3747-4 | [NEI] Oscillatory potentials findings | N |
LL3748-2 | [NEI] Reference electrode location | N |
LL3750-8 | [NEI] ERG procedure standard followed | N |
LL3751-6 | [NEI] ERG vendor and model used | N |
LL3752-4 | [NEI] ISCEV standard protocol used | N |
LL3756-5 | [NEI] Ocular motility findings | N |
LL3757-3 | [NEI] Anterior chamber angle findings | N |
LL3758-1 | [NEI] Visual field defect findings | N |
LL3760-7 | [NEI] Visual field findings by confrontatoin | N |
LL3761-5 | [NEI] Ocular fundus angiography findings | N |
LL3762-3 | [NEI] Pupillary response findings | N |
LL3763-1 | [NEI] Optical coherent tomography (OCT) findings | N |
LL3764-9 | [NEI] Chorioretinal findings | N |
LL3767-2 | [NEI] Glaucoma type | N |
LL3768-0 | [NEI] Optic nerve exam findings | N |
LL3771-4 | [NEI] Objective refraction method | N |
LL3773-0 | [NEI] Anterior chamber slit lamp findings | N |
LL3774-8 | [NEI] Conjunctiva and sclera slit lamp findings | N |
LL3775-5 | [NEI] Cornea slit lamp findings | N |
LL3776-3 | [NEI] Iris slit lamp findings | N |
LL3777-1 | [NEI] Lens slit lamp findings | N |
LL3779-7 | [NEI] Lids and lashes slit lamp findings | N |
LL3780-5 | [NEI] Pupil shape slit lamp findings | N |
LL3781-3 | [NEI] Vitreous slit lamp findings | N |
LL3787-0 | [NEI] Nystagmus type | N |
LL3788-8 | [NEI] Refraction method | N |
LL3816-7 | Nursing WDL or assessment text | N |
LL3860-5 | DBS collection method | N |
LL3871-2 | [NEI] VEP result | N |
LL3872-0 | [NEI] Pigmentation | N |
LL3882-9 | [APTA] Surgery relevant to physical therapy | N |
LL3885-2 | Muscle strength | N |
LL3896-9 | Burial | |
N |
LL3943-9 | Absent | |
N |
LL3944-7 | Gastric cancer surgical resection types | N |
LL3958-7 | Devices used for cardiac catheterization | N |
LL3971-0 | NCHS_Tabulated Race | N |
LL3991-8 | CDC_Transmission setting | N |
LL4003-1 | Sources used to estimate activity metabolic rate | N |
LL4004-9 | Sources used to adjust exercise MET | N |
LL4005-6 | Sources used for predicted RMR | N |
LL4006-4 | Sources used for population RMR | N |
LL4007-2 | Physical Activity Guidelines | N |
LL4012-2 | Yes| |
N |
LL402-9 | MERS_TH_2_Service | N |
LL4022-1 | Physical therapy degree | N |
LL4023-9 | Physical therapy highest education | N |
LL4024-7 | ClinVar| |
N |
LL4025-4 | Allelic phase | N |
LL403-7 | MERS_TH_3_Event type | N |
LL4037-9 | Calorimetry methods | N |
LL404-5 | MERS_TH_4_Med event | N |
LL405-2 | MERS_TH_5_Proc-tx-surg event | N |
LL4052-8 | Prenatal test | |
N |
LL406-0 | MERS_TH_6_Food-nutrition event | N |
LL4064-3 | Gene sequencing | |
N |
LL408-6 | MERS_TH_8_Accident event | N |
LL4081-7 | Apical| |
N |
LL409-4 | MERS_TH_9_Nursing care event | N |
LL410-2 | MERS_TH_10_Equip-device event | N |
LL411-0 | MERS_TH_11_Lab event | N |
LL4118-7 | Outdoor activities | N |
LL412-8 | MERS_TH_12_Transfusion event | N |
LL4120-3 | PCORI_response_method | N |
LL4121-1 | PCORI_response_source | N |
LL4122-9 | yes| |
N |
LL4123-7 | PCORI_Smoked_v_non-smoked_tobacco | N |
LL4124-5 | Expedite| |
N |
LL4125-2 | Laboratory| |
N |
LL4126-0 | PCORI_Cause_of_death_rank | N |
LL413-6 | MERS_TH_13_Admin event | N |
LL4135-1 | Platelet aggregation inhibitors | N |
LL4136-9 | Anticoagulant medications | N |
LL4137-7 | Preoperative procedures | N |
LL414-4 | MERS_TH_14_Complaint event | N |
LL415-1 | MERS_TH_15_Eviron-safety event | N |
LL416-9 | MERS_TH_16_Crime-harm-disappear event | N |
LL417-7 | MERS_TH_17_Adverse event | N |
LL418-5 | MERS_TH_18_Tech contributing factor | N |
LL419-3 | MERS_TH_19_Org contributing factor | N |
LL420-1 | MERS_TH_20_Comm-documentation factor | N |
LL4207-8 | Imputed parts of DOD | N |
LL4208-6 | Excellent| |
N |
LL421-9 | MERS_TH_21_Environ contributing factor | N |
LL422-7 | MERS_TH_22_Pt contibuting factor | N |
LL423-5 | MERS_TH_23_Staff contributing factor | N |
LL424-3 | MERS_TH_24_Delay-premature factor | N |
LL4347-2 | Low grade| |
N |
LL4348-0 | Surgical margin types | N |
LL4352-2 | Methylation techniques | N |
LL4353-0 | Reason vaccine not received | N |
LL4356-3 | Relationships | N |
LL4360-5 | Physician| |
N |
LL4363-9 | RV genotype | N |
LL4376-1 | [CAP] Procedure for tumor specimen collection | N |
LL4384-5 | [CAP] Architectural Patterns | N |
LL4390-2 | CAP_breast specimen origin | N |
LL4421-5 | Prescreen Influenza Sample | N |
LL4428-0 | CMS Living arrangement | N |
LL4436-3 | [CAP] Melanoma Procedure | N |
LL4455-3 | [CAP] Additional Pathologic Findings | N |
LL4456-1 | [CAP] Lymphadenectomy | N |
LL4463-7 | NKDEP_RRT treatment preference | N |
LL4470-2 | CMS_LCDS Payer information | N |
LL4472-8 | CMS_LCDS Discharge location | N |
LL4562-6 | [CAP] Microcalcifications in breast cancer | N |
LL4564-2 | [CAP] Margins | N |
LL4572-5 | [CAP] Melanoma margins | N |
LL4575-8 | Provider role | N |
LL4579-0 | Reason for no birth control | N |
LL4631-9 | Father of baby | |
N |
LL4636-8 | NIDDK_CKD education topics | N |
LL4653-3 | Role of person in accident | N |
LL4655-8 | Mechanism of force that caused injury | N |
LL4657-4 | Intoxication cause | N |
LL4674-9 | Burial | |
N |
LL4703-6 | Categories of Leukocytes | N |
LL4705-1 | NIDDK_patient health goals | N |
LL4706-9 | NIDDK_functional areas | N |
LL4707-7 | NIDDK_Health events | N |
LL4708-5 | NIDDK_Symptoms | N |
LL4709-3 | NIDDK_Mental health issues | N |
LL4710-1 | NIDDK_Challenges | N |
LL4711-9 | NIDDK_Treatment affected by challenges | N |
LL4747-3 | NTDS_DG_01_Co-morbid Conditions_v2018 | N |
LL4748-1 | NTDS_ED_17_Drug Screen | N |
LL4749-9 | Blunt| |
N |
LL4750-7 | NTDS_F01_Payment source_v2 | N |
LL4752-3 | NTDS_I_14_Protective devices | N |
LL4753-1 | NTDS_Q_01_Hospital Complications_v2 | N |
LL484-7 | DEEDS4.05_Source of Referral | N |
LL4904-0 | Body position &or immobilizers | N |
LL4906-5 | Factors related to rescue | N |
LL4939-6 | Alone | |
N |
LL494-6 | DEEDS4.27_1st temp site | N |
LL4955-2 | Anticoagulant medications - ADAPTABLE | N |
LL4960-2 | ADAPTABLE Race list | N |
LL4963-6 | 81 mg | |
N |
LL4999-0 | Circulatory assistive devices | N |
LL5-0 | MDS_90_Admitted from | N |
LL5007-1 | Molecular lab test antibiotic resistance method | N |
LL5008-9 | Phenotypic method for antibiotic resistance | N |
LL5009-7 | APTA_Airway clearance techniques | N |
LL5011-3 | APTA_Motor function training | N |
LL5012-1 | APTA_Therapeutic exercise | N |
LL5013-9 | APTA_Functional training | N |
LL5015-4 | APTA_Integumentary repair and protection | N |
LL5016-2 | APTA_Instruction provided | N |
LL5017-0 | APTA_Manual therapy techniques | N |
LL5018-8 | APTA_Biophysical agent | N |
LL5021-2 | APTA_Movement system diagnosis | N |
LL5023-8 | Reason for difficult intubation | N |
LL5025-3 | Reason rescue operation was canceled | N |
LL5028-7 | German DIMD_Mental status | N |
LL5054-3 | Manual| |
N |
LL5110-3 | EOC public document types | N |
LL5202-8 | EOC Inter-agency document types | N |
LL5334-9 | PRAPARE_Food| |
N |
LL5348-9 | PRAPARE_Race | N |
LL5359-6 | Vomiting| |
N |
LL5389-3 | Setting of exposure to hazard | N |
LL5496-6 | Religious belief | N |
LL5542-7 | Intubation tube types | N |
LL5544-3 | EMS Positions and/or immobilizers | N |
LL5552-6 | COVID19 exposures | N |
LL5563-3 | Reasons specimen not collected | N |
LL5565-8 | Mode of discovery for tumor | N |
LL5580-7 | Birth location | N |
LL5598-9 | Animal exposure | N |
LL5625-0 | Substances - NIDA-ASSIST | N |
LL57-1 | CR_1040_Cancer stager | N |
LL5713-4 | AAPCHO - Services Provided | N |
LL5721-7 | Debridement method | N |
LL5739-9 | CMS_LCDSv4 Discharge location | N |
LL5770-4 | AAPCHO - Provided Services | N |
LL5826-4 | Spine Tango - Work status | N |
LL5827-2 | Spine Tango - Follow-up Interval | N |
LL5828-0 | Spine Tango - Therapeutic goals/measures | N |
LL5829-8 | Spine Tango - Meds Spinal surgery/pathology | N |
LL5832-2 | Spine Tango - Complications Type | N |
LL5833-0 | Spine Tango - Therapeutic consequences | N |
LL5834-8 | Sping Tango - Individual Consequences | N |
LL5835-5 | Spine Tango - Rehabilitation | N |
LL5838-9 | Spine Tango - Degeneration Type | N |
LL5839-7 | Spine Tango - Deformity Type | N |
LL5840-5 | Spine Tango - Predominant Etiology | N |
LL5841-3 | Spine Tango - Fracture/Trauma Type | N |
LL5845-4 | Pathological fracture cause | N |
LL5850-4 | Infection specification | N |
LL5851-2 | Affected structures | N |
LL5852-0 | Spine Tango - Tumor Type | N |
LL5853-8 | Spine Tango - Tumor localization | N |
LL5862-9 | Vaccine administration location | N |
LL5882-7 | COVEX Work Situation | N |
LL5883-5 | COVEX Work Settings | N |
LL5889-2 | COVEX - Household Members | N |
LL5893-4 | EuroSpine Repeat Surgery Reason | N |
LL5897-5 | EuroSpine - Main pathology | N |
LL5901-5 | EuroSpine - Therapeutic goals | N |
LL5903-1 | Anterior access | N |
LL5904-9 | Posterior access | N |
LL5906-4 | EuroSpine - Surgeon Credentials | N |
LL5907-2 | EuroSpine - Technology | N |
LL5912-2 | Decompression | N |
LL5914-8 | Fusion promoting measures | N |
LL5915-5 | Fusion material | N |
LL5916-3 | EuroSpine - Stabilized rigid | N |
LL5917-1 | Deformity correction | N |
LL5918-9 | Stabilization motion preserving | N |
LL5919-7 | Other surgial measures | N |
LL5920-5 | Intraop adverse event | N |
LL5921-3 | Measures during index surgery | N |
LL5922-1 | Intraop general complications | N |
LL5923-9 | PostOp Surgical Complications | N |
LL5924-7 | PostOp General Complications | N |
LL5925-4 | Re-intervention after index surgery | N |
LL5961-9 | Spine Tango - Degeneration Type_Secondary | N |
LL5968-4 | Spine Fusion Measures | N |
LL5970-0 | Injury associated activity | N |
LL5971-8 | Reason CPR discontinued | N |
LL5973-4 | DIMDI_Neurological assessment | N |
LL5997-3 | Cryptosporidium species | N |
LL6006-2 | Employment Situations | N |
LL6019-5 | Hearing Loss - Configuration | N |
LL6030-2 | CVD-19 - school age - reason not follow learning | N |
LL6049-2 | Reason for missed appointments w/code | N |
LL6050-0 | Therapeutic Antibody Treatment | N |
LL6053-4 | Reason for missed appointments w/o code | N |
LL6057-5 | Reason for missed medication w/code | N |
LL6061-7 | Expense coverage | N |
LL6080-7 | Organs donated | N |
LL6086-4 | Sources of information | N |
LL6087-2 | LASIK Information Sources | N |
LL6095-5 | Medical attention type | N |
LL6100-3 | NEI Race List | N |
LL613-1 | CR_193 | N |
LL6167-2 | Internet types | N |
LL6168-0 | Education provider | N |
LL6169-8 | Post high school plans | N |
LL6194-6 | Reason not to repeat/recommend procedure | N |
LL6197-9 | Yes| |
N |
LL6199-5 | Child care providers | N |
LL622-2 | USSG-FHT gender | N |
LL6226-6 | Specular Microscopy Analysis Method | N |
LL6242-3 | Assisted mobility devices | N |
LL6266-2 | POLST discuss part | N |
LL636-2 | MDSv3_A0800 | N |
LL637-0 | MDSv3_A2100 | N |
LL6566-5 | PhenX11701_Sexual orientation description other | N |
LL6574-9 | Gender identity, other | N |
LL6576-4 | Biological sex assigned at birth, other | Y |
LL66-2 | CR_1130_Peds staging coding system | N |
LL67-0 | CR_1140_Peds stager | N |
LL740-2 | Special circumstances | N |
LL777-4 | OASIS-C_M1032 | N |
LL8-4 | MDS_156_Primary language | N |
LL830-1 | NBS events | N |
LL869-9 | AnginaLoc | N |
LL870-7 | AnginaRad | N |
LL871-5 | AnginaType | N |
LL889-7 | DVTDxSource | N |
LL939-0 | NAACCR_7480 | N |
LL987-9 | TIMP_27_Environment | N |
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright